A RANDOMIZED PHASE III STUDY OF TAS-118 VERSUS S-1 IN PATIENTS WITH GEMCITABINE-REFRACTORY ADVANCED PANCREATIC CANCER

Trial Profile

A RANDOMIZED PHASE III STUDY OF TAS-118 VERSUS S-1 IN PATIENTS WITH GEMCITABINE-REFRACTORY ADVANCED PANCREATIC CANCER

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs Gimeracil/oteracil/tegafur/folinic acid (Primary) ; Gimeracil/oteracil/tegafur
  • Indications Carcinoma; Pancreatic cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms GRAPE
  • Sponsors Taiho Pharmaceutical
  • Most Recent Events

    • 03 Aug 2017 Status changed from active, no longer recruiting to completed.
    • 06 Jun 2017 Primary endpoint (Overall survival) has not been met as per the results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 06 Jun 2017 Results (n=586) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top